In summary, our findings together with the low mutation rate of SMURF2 in human cancer (0.19% for prostate cancer and 0.48% for breast cancer [36]), suggest that the main alteration in the expression of SMURF2 in prostate and breast tumors is associated with its localization. Here, SMURF2 is linked to prostate cancer.